S&P DJI Announces September 2026 Quarterly Rebalance
Filed with ASX · · 6 pages · English
Vitrafy Life Sciences Ltd. on 6ix
Earlier from Vitrafy Life Sciences
- Vitrafy enters U.S. Cell & Gene Therapy Market
- FY26 Full Year Results Presentation
- FY26 Appendix 4E and Annual Report
- FY26 Corporate Governance Statement
- FY26 Appendix 4G
Later from Vitrafy Life Sciences
- Vitrafy enters partnership with Versiti Blood Health
- Change to CEO Remuneration and Employment Terms
- Investor Roadshow Presentation
- 2026 Notice of Annual General Meeting
- Appointment of Chief Financial Officer
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences